Metacrine Public
Metacrine is a clinical-stage biopharmaceutical company that specializes in developing innovative drugs to treat liver and gastrointestinal diseases. Their main focus is on the farnesoid X receptor (FXR) program, which targets multiple liver and GI diseases. In addition to the FXR program, Metacrine also explores other drug targets through their internal drug discovery and development capabilities. Their goal is to pioneer differentiated therapies for patients with GI and liver diseases. Recently, the FXR Program has been acquired by Organovo. For more information, please visit www.organovo.com.
Investors Number:
14
Technology:
Immunotherapy
Last Funding Date:
2019
Headquarters:
San Diego, California, United States
Founded Date:
2015
Industry:
PharmTech
Employee Number:
11-50
Last Funding Type:
Debt Financing
Funding Status:
IPO
Investor Type:
IPO
Total Funding:
173000000
Estimated Revenue:
$10M to $50M